Market Closed - Nasdaq 04:00:00 2024-02-28 pm EST 5-day change 1st Jan Change
16.02 USD -1.72% Intraday chart for NovoCure Limited +1.26% +7.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Evercore ISI Adjusts Price Target on NovoCure to $15 From $14, Keeps In Line Rating MT
Novocure Q4 Net Loss Widens, Revenue Rises MT
Transcript : NovoCure Limited, Q4 2023 Earnings Call, Feb 22, 2024
Earnings Flash (NVCR) NOVOCURE Reports Q4 Revenue $133.8M MT
NovoCure Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Sector Update: Health Care Stocks Softer Late Thursday Afternoon MT
Top Midday Gainers MT
Sector Update: Health Care Stocks Weaker Thursday Afternoon MT
NovoCure Says US FDA Accepts Its Premarket Approval Application for Tumor Treating Fields in Lung Cancer; Shares Rise MT
Novocure Shares Rise 17% After FDA Accepts Pre-Market Application DJ
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer CI
Transcript : NovoCure Limited Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 07:30 AM
NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma CI
NovoCure Reports Higher Q4 Preliminary Revenue; Shares Rise MT
Novocure Preliminary Full Year 2023 Net Revenues Of $509 Mln And Q4 Net Revenues Of $134 Mln RE
Novocure Names Nicolas Leupin as Chief Medical Officer MT
NovoCure Limited Announces Executive Changes CI
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer CI
Transcript : NovoCure Limited Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 03:30 PM
Sector Update: Health Care Stocks Ease Tuesday Afternoon MT
Sector Update: Health Care MT
NovoCure to Cut Workforce by 13% in Restructuring Plan MT
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability CI
Wedbush Adjusts NovoCure Price Target to $21 From $23, Maintains Neutral Rating MT
Transcript : NovoCure Limited, Q3 2023 Earnings Call, Oct 26, 2023
Chart NovoCure Limited
More charts
NovoCure Limited is a global oncology company, which is principally engaged in the development, manufacturing and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields therapy has applicability across solid tumor types and lines of therapy. It is conducting phase three pivotal studies evaluating the use of TTFields in non-small cell lung cancer (NSCLC), ovarian cancer, brain metastases from NSCLC, and pancreatic cancer. The Company's key priorities are to drive commercial adoption of Optune and Optune Lua, its commercial TTFields devices. The Company markets Optune in the United States, Germany, Japan and other countries. The Company markets Optune Lua in the United States and European Union. It also has a licence to market Optune in China, Hong Kong, Macau and Taiwan.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
16.02 USD
Average target price
25 USD
Spread / Average Target
  1. Stock
  2. Equities
  3. Stock NovoCure Limited - Nasdaq
  4. News NovoCure Limited
  5. JPMorgan Downgrades NovoCure to Underweight From Neutral, Adjusts Price Target to $50 From $99
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.